About Omega Funds
Omega Funds is a venture capital firm founded in 2004. It is primarily based out of Boston, United States. As of May 2025, Omega Funds is an active investor, having invested in 135 companies, with 8 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it led the Undisclosed Seed round of Ousia Pharma.
Overall, Omega Funds portfolio has seen 1 unicorn, 45 IPOs and 44 acquisitions including key companies like BridgeBio, Evotec and Juno Therapeutics. A lot of funds co-invest with Omega Funds, with names like EcoR1 sharing a substantial percentage of its portfolio.
Omega Funds has team of 26 people including 13 partners.
Key Metrics
Team Members
, &
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B &
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Deals in last 12 months
Omega Funds' List of Top Investments
Omega Funds has a portfolio of 135 companies, one of which is a Unicorn. Their most notable investments are in Chord Therapeutics and JenaValve Technology.Their portfolio spans across United States, United Kingdom, GermanyÌý²¹²Ô»å 15 more locations. They have invested in Life Sciences, High Tech, Enterprise ApplicationsÌý²¹²Ô»å 13 other sectors, across stages such as Series A, Series B Ìý²¹²Ô»å 4 more. Here is the list of top investments by Omega Funds:
1. BridgeBio
Developer of therapeutics for the treatment of genetic diseases. It utilizes a mapping of various genetic disease landscapes to identify opportunities for therapeutic intervention. The company's drug candidates include PTCH1-inhibitor for Gorlin syndrome and S1P-lyase inhibitor for Darier disease and Hailey-Hailey disease and others.
Key facts about BridgeBio
- Founded Year: 2015
- Location: Palo Alto (United States)
- Annual Revenue: $9.3M as on Dec 31, 2023
- Stage: Acquired
- Total Funding till date: $434M
- Investors: Aisling Capital, Athyrium Capital Management and 20 Others
- Latest Funding Round: Post IPO, Apr 30, 2024, $200M
- Highlight: Acquired
2. Evotec
Key facts about Evotec
- Founded Year: 1993
- Location: Hamburg (Germany)
- Stage: Public
- Total Funding till date: $25M
- Employee Count: 252 as on Dec 31, 2020
- Investors: Omega Funds, Eiffel Investment Group and 20 Others
- Latest Funding Round: Grant (prize money), Jun 02, 2023, $1.7M
- Highlight: Public
Juno Therapeutics is developing T cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Company's lead therapies are for the treatment of acute lymphoblastic leukemia and adult B-cell malignancies. Other programs in development are for the treatment of acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL) and non-small cell lung cancer (NSCLC).
Key facts about Juno Therapeutics
- Founded Year: 2013
- Location: Seattle (United States)
- Annual Revenue: $112M as on Dec 31, 2017
- Stage: Acquired
- Total Funding till date: $317M
- Employee Count: 520 as on Dec 31, 2017
- Investors: Ridgeback Capital Management, BB Biotech and 14 Others
- Latest Funding Round: Post IPO, Oct 05, 2017, $31.1M
- Highlight: Acquired
Developer of cell-based therapies for cancer treatment. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. It allows engineering and designing of optimized therapeutic gene circuits for various therapeutic applications. It offers CAR-NK-based therapies for multiple cancer and tumors.
Key facts about Senti Biosciences
- Founded Year: 2016
- Location: San Francisco (United States)
- Annual Revenue: $2.56M as on Dec 31, 2023
- Stage: Public
- Total Funding till date: $158M
- Investors: Ridgeback Capital Management, Omega Funds and 30 Others
- Latest Funding Round: Post IPO, Dec 02, 2024, $37.6M
- Highlight: Public
5.
Developer of drugs based on T-cell receptor technology for the treatment of cancer. The company's proprietary technology is focused on small protein molecules called ImmTACs (Immune mobilizing monoclonal TCRs Against Cancer) that enable the immune system to recognize and kill cancerous or bacterially/virally infected cells. They enable this by recognizing peptide-HLA complexes on the surface of cancer cells and effecting a potent and specific T cell response to destroy cancer cells (through an anti-CD3 antibody fragment). Its lead candidate is IMCgp100, a novel bi-specific immunotherapeutic, which is used for the treatment of uveal melanoma.
Key facts about Immunocore
- Founded Year: 2008
- Location: Abingdon (United Kingdom)
- Annual Revenue: £179M as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $601M
- Employee Count: 293 as on Jan 31, 2022
- Investors: NeoMed, Rock Springs Capital and
- Latest Funding Round: Post IPO, Jul 18, 2022, $140M
- Highlight: Public
Omega Funds' Year-on-Year Investment Trends
Omega Funds has invested in 135 companies over the last 19 years, with an average of 7 new investments annually in the last 10 years. In 2024, it made 10 investments, while as of May 2025, it has made 2 investments in this year. Its most recent first time investment was in Ousia Pharma and most recent follow-on round was in Beta Bionics.
Year | No. of Investments | ||
|---|---|---|---|
1stÌý¸é´Ç³Ü²Ô»å | Follow-on | Total | |
2025 (YTD) | 2 | 0 | 2 |
2024 | 8 | 2 | 10 |
2023 | 5 | 3 | 8 |
2022 | 4 | 3 | 7 |
2021 | 13 | 5 | 18 |
2020 | 14 | 0 | 14 |
2019 | 5 | 2 | 7 |
2018 | 5 | 4 | 9 |
2017 | 3 | 2 | 5 |
2016 | 1 | 0 | 1 |
Get Omega Funds' portfolio delivered to your inbox!
Omega Funds' Investments by Stage
Omega Funds has made 28 investments in Series A stage with an average round size of $77.5M, 25 investments in Series B stage with an average round size of $81M and 14 investments in Series C stage with an average round size of $96.5M.Note: We have considered here, only first round of investments
Stage of entry | No. of Investments |
|---|---|
Series A | 28 |
Series B | 25 |
Series C | 14 |
Post IPO | 7 |
Seed | 4 |
Others | 4 |
Omega Funds' Investments by Sector
Omega Funds has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Enterprise Applications and Healthcare. Notably, it has invested in 113 Enterprise (B2B) companies, 112 Tech companies, 11 Tech hardware companies and at least 9 companies focusing on Software.
Note: We have considered here, only first round of investments
Sector | No. of Investments |
|---|---|
Life Sciences | 79 |
High Tech | 15 |
Sustainability Tech | 8 |
Enterprise Applications | 4 |
Healthcare | 4 |
Others | 4 |
Omega Funds' Investments by Geography
Omega Funds has made most investments in United States (58), followed by Switzerland where it has made 7 investments.
Note: We have considered here, only first round of investments
Country | No. of Investments |
|---|---|
United States | 58 |
Switzerland | 7 |
United Kingdom | 6 |
Canada | 2 |
Denmark | 2 |
Others | 8 |
Omega Funds' recent investments
Here are the most recent investments by Omega Funds:
Date | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 06, 2025 | Denmark | Seed | Undisclosed | - | |
Mar 03, 2025 | United States | Series A | $187M | ||
Dec 19, 2024 | United States | Series C | $90.8M | [+6] | |
Dec 17, 2024 | United States | Series C | $208M | TCG Crossover [+10] | |
Nov 13, 2024 | United States | Series E | $60M | [+6] |
Get the detailed list of all investments by Omega Funds. Download now!Unicorns in Omega Funds' Portfolio
Here is a list of unicorns in Omega Funds' portfolio:
ÃØÃÜÑо¿Ëù Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
33 | Provider of osmotic pump for subcutaneous drug delivery | 1995 | Boston | Series J | dladcdr |
IPOs and Publicly Listed companies in Omega Funds' Portfolio
Here are Omega Funds' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 06, 2025 | Jul 24, 2024 | Series B | $196M | |
Jan 30, 2025 | Aug 28, 2023 | Series D | $100M | |
Oct 11, 2024 | Jun 02, 2022 | Series A | $200M | |
Sep 13, 2024 | Mar 06, 2023 | Series B | $108M | |
Jun 28, 2024 | Mar 07, 2024 | Series C | $259M |
Acquired companies in Omega Funds' Portfolio
Here are Omega Funds' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 01, 2025 | Aug 24, 2020 | Series B | $148M | |
Mar 03, 2025 | Jan 09, 2023 | Series C | $60M | |
Jul 25, 2024 | Jul 19, 2013 | Series C | $73.4M | |
Jul 08, 2024 | Jun 30, 2016 | Series A | $51.5M | |
May 30, 2024 | Nov 14, 2023 | Series A | $65M |
_1548135965397.png?height=40&width=40){kind=logo}
Team profile of Omega Funds
Omega Funds has a team of 26 membersÌýincluding 13 Partners, 3 Venture Partners and 3 PrincipalsÌýlocated in United States, Switzerland and . Omega Funds' team does not sit on the board of any company as of now.Here is a list of top team members in Omega Funds:
Name | Designation | Location | Board Memberships | Contact details |
|---|---|---|---|---|
Partner | Boston | - | ||
Partner | Geneva | - | ||
Partner | Geneva | - | ||
Partner | Boston | - | ||
Partner | United States | - | - | |
Partner | Lexington | - | - | |
Partner | Switzerland | - | ||
Partner | Toronto | - | ||
Partner | Boston | - | ||
Partner | Cambridge | - | - | |
Partner | Cambridge | - | - |
Get the full list of Omega Funds' team & partners for free. Download now!Co-investors of Omega Funds
Over the past 19 years, 562 investors have co-invested in Omega Funds's portfolio companies.
- Invested before Omega Funds:ÌýHHS, Atlas Venture and 191 others have invested in rounds before Omega Funds. There are 7 companies where HHS has invested before Omega Funds and 6 companies where Atlas Venture has invested before Omega Funds.
- Top Co-investors of Omega Funds:Ìý215 investors entered a company along with Omega Funds. These include investors like EcoR1 (8 companies).
- Invested after Omega Funds:ÌýA total of 154 investors have invested in Omega Funds's portfolio after their investments. Top Investors include Alexandria (5 companies), Bain Capital Life Sciences (4 companies) and Invus (4 companies).
Get full list of Omega Funds' co-investors delivered to your inbox!
Recent News related to Omega Funds
•
•
•
•
intelligence360•Mar 17, 2025•Callio Therapeutics, Frazier Life Sciences, Jeito, Novo Holdings and 7 others
•
Pharmaceutical Technology•Mar 04, 2025•Callio Therapeutics, Frazier Life Sciences, Jeito, Omega Funds and 3 others
•
Jinglingshuju•Mar 04, 2025•Callio Therapeutics, Frazier Life Sciences, Jeito, Novo Holdings and 6 others
•
BioPharmaDive•Mar 03, 2025•Hummingbird Bioscience, Frazier Healthcare Partners, Jeito, Novo Holdings and 9 others
•
GlobeNewswire•Mar 03, 2025•Jeito, Callio Therapeutics, Hummingbird Bioscience, Frazier Life Sciences and 8 others
•
•
intelligence360•Jan 17, 2025•Aviceda Therapeutics, Omega Funds, TCG Crossover, Enavate Sciences and 3 others
